Form 10-Q Valeant Pharmaceuticals For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Valeant (VRX) PT Cut to $33 at RBC Capital
June 8, 2016 7:07 AM EDTRBC Capital analyst Douglas Miehm lowered estimate and his price target on Sector Perform-rated Valeant Pharmaceuticals (NYSE: VRX) to $33.00 (from $58.00) following mixed earnings, which were overshadowed by sharply lower guidance.
Miehm commented, "Total revenue guidance was lowered to $9.9-10.1B, from $11.0-11.2B and cash EPS guidance... More
Valeant Pharma (VRX) 1Q16 Was A Clean-Up Quarter - Guggenheim
June 8, 2016 6:57 AM EDTGuggenheim analyst, Louise Chen, defended Valeant Pharmaceuticals (NYSE: VRX) as she continues to believe that VRX's long-term growth prospects are underappreciated. Upside to expectations could come from: 1) divestment of non-core products to pay down debt; 2) meeting or beating quarterly earnings in '16; and, 3)... More
Valeant (VRX) PT Cut to $38 at BMO Capital
June 8, 2016 6:27 AM EDTBMO Capital analyst Alex Arfaei reiterated a Market Perform rating and cut his price target on Valeant Pharmaceuticals (NYSE: VRX) to $38.00 (from $44.00) after the company cut guidance. While the firm expected the cut, it was greater than they and the market expected.
Arfaei commented, "Although we expected Valeant to lower its guidance, the magnitude of the downward revision was greater than we and the market expected. This... More
Valeant Pharma (VRX) Files 10-Q
June 7, 2016 5:19 PM EDTValeant Pharma (NYSE: VRX) filed its form 10-Q with the SEC. The long-awaited filing allows the company to avoid default.
... More